AbCellera Biologics Inc. ABCL Cash and cash equivalents, end of period
Cash and cash equivalents, end of period at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations.
The official record: AbCellera Biologics Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about AbCellera Biologics Inc.'s cash and cash equivalents, end of period.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AbCellera Biologics Inc.'s cash and cash equivalents, end of period?
- AbCellera Biologics Inc. (ABCL) reported cash and cash equivalents, end of period of $103.8M in Q1 2026.
- How has AbCellera Biologics Inc.'s cash and cash equivalents, end of period changed year-over-year?
- AbCellera Biologics Inc.'s cash and cash equivalents, end of period decreased by 44.4% year-over-year, from $186.56M to $103.8M.
- What is the long-term trend for AbCellera Biologics Inc.'s cash and cash equivalents, end of period?
- Over 4 years (2021 to 2025), AbCellera Biologics Inc.'s cash and cash equivalents, end of period has grown at a -25.4% compound annual growth rate (CAGR), from $501.14M to $155.25M.